LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway

  • Authors:
    • Fan Li
    • Weimin Yang
    • Dongsheng Guo
    • Zhiquan Hu
    • Hua Xu
    • Zhangqun Ye
  • View Affiliations

  • Published online on: March 22, 2011     https://doi.org/10.3892/or.2011.1227
  • Pages: 1629-1637
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

One aspect of chemotherapy insensitivity and resistance results from induction of epidermal growth factor receptor (EGFR) internalization and initial DNA damage repair in response to DNA-damaging stimuli, such as cisplatin (CDDP). Previously, we found that leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), as one of the natural ligands of EGFR, could combine with and down-regulate the expression of EGFR in bladder cancer cells. This finding interested us and we hypothesized that LRIG1 could be a novel candidate for facilitating cisplatin-induced bladder cancer cell lesions. To investigate this further, we overexpressed LRIG1 with an adenovirus vector in EJ/T24 bladder cancer cells and investigated total EGFR, nuclear expression of phosphorylated EGFR (pEGFR) and cell lesions with exposure to CDDP. CDDP-induced nuclear pEGFR levels accumulated with time and were decreased by LRIG1 overexpression. LRIG1-transduced cells treated with CDDP had more severe DNA damage, cellular apoptosis, growth inhibition and reversal of invasion. These preclinical studies indicate that LRIG1 may represent a new therapeutic approach to improve the response of bladder cancer to chemotherapy through a novel pathway.

Related Articles

Journal Cover

June 2011
Volume 25 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li F, Yang W, Guo D, Hu Z, Xu H and Ye Z: LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway. Oncol Rep 25: 1629-1637, 2011.
APA
Li, F., Yang, W., Guo, D., Hu, Z., Xu, H., & Ye, Z. (2011). LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway. Oncology Reports, 25, 1629-1637. https://doi.org/10.3892/or.2011.1227
MLA
Li, F., Yang, W., Guo, D., Hu, Z., Xu, H., Ye, Z."LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway". Oncology Reports 25.6 (2011): 1629-1637.
Chicago
Li, F., Yang, W., Guo, D., Hu, Z., Xu, H., Ye, Z."LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway". Oncology Reports 25, no. 6 (2011): 1629-1637. https://doi.org/10.3892/or.2011.1227